Literature DB >> 16633027

Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications.

Mari Tanaka1, Murat Dogru, Yoji Takano, Minori Miyake-Kashima, Naoko Asano-Kato, Kazumi Fukagawa, Kazuo Tsubota, Hiroshi Fujishima.   

Abstract

BACKGROUND: Atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) are chronic inflammatory allergic diseases that are associated with some common conjunctival and corneal complications.1 The clinical corneal manifestations of both entities may include superficial punctate keratitis, macroerosions, corneal ulceration, plaque formation, corneal neovascularization, and lipid infiltration.
PURPOSE: To quantitatively evaluate the early ocular surface inflammation before and after mitomycin C (MMC)-aided papillary resection in severe allergy patients with corneal complications.
METHODS: Three eyes with VKC and 5 eyes with AKC were included in this study. All eyes had cobblestone-like papillae on the upper tarsal conjunctiva and corneal complications such as corneal ulcers, defect, or erosions that were refractory to conventional treatment of more than 2 weeks. Papillary resection with intraoperative 0.05% MMC application for 5 minutes on the palpebral conjunctiva was carried out in all eyes. Corneal and conjunctival findings were evaluated before and 1 week and 2 weeks after surgery. Brush cytology (BC) and evaluation of tear eosinophilic cationic protein (ECP) levels by radioimmunoassay techniques were performed as well pre- and postoperatively.
RESULTS: Corneal and conjunctival complications resolved in all patients within 7 days after resection. Postoperative tear ECP levels decreased significantly with papillary resection (P< 0.05). Concomitant brush cytology showed a significant decrease in the number of eosinophils and neutrophils following papillary resection (P < 0.05).
CONCLUSION: MMC-aided papillary resection provided a dramatic decrease in ocular surface inflammation as evidenced by decrease in the number of inflammatory cells as well as tear ECP levels with a rapid improvement of clinical corneal and conjunctival findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633027     DOI: 10.1097/01.ico.0000183533.14899.8d

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis.

Authors:  Fang-Yu Liu; Hsin-Yu Liu; Hsiao-Sang Chu; Wei-Li Chen; Fung-Rong Hu; I-Jong Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-09       Impact factor: 3.117

2.  Management of vernal keratoconjunctivitis.

Authors:  Andrea Leonardi
Journal:  Ophthalmol Ther       Date:  2013-09-07

Review 3.  Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group.

Authors:  Jodhbir S Mehta; Wei-Li Chen; Arthur C K Cheng; Le Xuan Cung; Ivo J Dualan; Ramesh Kekunnaya; Nurliza Khaliddin; Tae-Im Kim; Douglas K Lam; Seo Wei Leo; Florence Manurung; Nattaporn Tesavibul; Dominique Bremond-Gignac
Journal:  Front Med (Lausanne)       Date:  2022-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.